Bristol-Myers Squibb Co.
Company Snapshot
Company Overview
Bristol-Myers Squibb Co. is a biopharmaceutical company headquartered in the U.S., with operations across North America, Europe, and emerging markets. Its revenue is driven by prescription medicines in oncology, immunology, cardiovascular disease, and fibrosis. In recent years, it has expanded its oncology portfolio through selective acquisitions of late-stage products and licensing agreements. At the same time, its immunology treatments have grown through targeted collaborations and in-market launches.
Bristol-Myers Squibb Co.’s business is organized into two main segments: growth portfolio and legacy portfolio. The growth portfolio comprises newer specialty medicines, particularly in oncology and immunology, which are driving revenue growth and contributing to market share gains in key regions. The legacy portfolio comprises established products that continue to generate steady revenue but face increasing competition from generics and pressures of market maturity.
Financial Highlights (FY 2025)
This information is available for BCC Research members only.
Bristol-Myers Squibb Co. In Reports
Bristol-Myers Squibb Co. In News
Company's Business Segments
- Growth Portfolio : Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Breyanzi, Camzyos, Zeposia, Abecma, Sotyktu, Krazati, Augtyro, Cobenfy, Other Growth Portfolio
- Legacy Portfolio : Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel, Abraxane, Other Legacy products.
Applications/End User Industries
- Oncology
- Innovative Treatments
- Cancer
- Immunotherapy
- Therapies
- Cardiovascular Diseases
- Immunological Disorders
- Fibrotic Diseases
- Melanoma
- Renal Cell Carcinoma
- Atrial Fibrillation
- Pulmonary Embolism
- Lymphoma
- Rheumatoid Arthritis
- Myelodysplastic
- Schizophrenia
- Healthcare
- Medicines
- Pharmaceuticals